Otsuka
Also known as: Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd. | Director of Division Dermatilogicals and Ophtalmolgicals, Otsuka Pharmaceutical Co., Ltd. | Director of Division of Dermatologicals and Ophthalmologicals, Otsuka Pharmaceutical Co., Ltd. | Division Dermatilogicals and Ophtalmolgicals, Otsuka Pharmaceutical Co., Ltd. | Kevin.TC-Cox@otsuka-us.com | Korea OIAA | Korea Otsuka International Asia Arab | Korea Otsuka International Asia Arab Co., Ltd. | Korea Otsuka Pharmaceutical Co., Ltd. | OBRI | OTSUKA | OTSUKA AMERICA | OTSUKA AMERICA PHARM | Otsuka America Pharmaceutical | Otsuka Australia Pharmaceutical Pty Ltd | Otsuka Beijing Research Institute | Otsuka Canada Pharmaceutical Inc. | Otsuka Frankfurt Research Institute GmbH | Otsuka Korea | Otsuka Medical Devices Co., Ltd. Japan | Otsuka Novel Products GmbH | Otsuka Pakistan Limited | Otsuka Pharamceutical Development & Commercialization, Inc. | OTSUKA PHARM | Otsuka Pharmaceutical Co., Ltd. | Otsuka Pharmaceutical Co., Ltd Japan (OPCJ) | Otsuka Pharmaceutical Company, Ltd. | Otsuka Pharmaceutical Corporation, Ltd. Japan | Otsuka Pharmaceutical Development and commercialization | Otsuka Pharmaceutical Development and Commercialization | Otsuka Pharmaceutical Development and Commercialization, Inc. | Otsuka Pharmaceutical Development & Commercialization | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) | Otsuka Pharmaceutical Europe Ltd | Otsuka Pharmaceutical Factory, Inc. | Otsuka Pharmaceutical, Inc., Philippines | Otsuka Pharmaceutical Italy S.r.l. | Otsuka Pharmaceuticals | Otsuka Pharmaceutical Vietnam | OTSUKA PHARM CO LTD | PT Otsuka Indonesia | Rosa.Real@otsuka-us.com | Taiho | Taiho Oncology, Inc. | Taiho Pharmaceutical Co., Ltd. | Taiho Pharmaceuticals CO Ltd. | Taiwan Otsuka Pharm. Co., Ltd | Thai Otsuka Pharmaceutical Co.,Ltd. | Zhejiang Otsuka Pharmaceutical Co., Ltd.
Highest phase reached
Phase 4
First clinical trial
Apr 1, 1992First marketed drug
Sep 17, 1996First NDA
Sep 17, 1996Last known activity
Dec 31, 2025
Timeline
1960s
- Jan 1, 1964
Otsuka— Founded
1990s
- Jun 2, 1993
Taiho Pharmaceutical— Acquired
- Jan 15, 1999
cilostazol— NDA Organization
2000s
- Jan 6, 2009
Nutrition & Sante— Acquired
2010s
- Oct 11, 2013
Astex Pharmaceuticals, Inc.— Acquired
- Jan 1, 2014
Avanir— Acquired
- Jan 1, 2015
Bicentury— Acquired
- Jul 10, 2015
brexpiprazole— Marketing Organization
- Dec 2, 2016
SuperGen— Acquired
- Mar 2, 2017
Neurovance, Inc.— Acquired
- Jul 10, 2018
ReCor Medical— Acquired - Sep 4, 2018
Visterra, Inc.— Acquired
2020s
- Sep 30, 2022
futibatinib— NDA Secondary Org
Drugs by trial phase (257 distinct, 813 trials)
Phase 4 (33 own, 5 via acquisition)
Phase 3 (72 own, 22 via acquisition)
Phase 2 (49 own, 35 via acquisition)
Phase 1 (22 own, 16 via acquisition)
Other trials (3 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acquired Immunodeficiency Syndrome
- Adenocarcinoma
- Alcohol Drinking
- Alcoholism
- Alzheimer Disease
- Anemia
- Angina Pectoris
- Angina Pectoris, Variant
- Anxiety Disorders
- Arterial Occlusive Diseases
- Arteriosclerosis
- Arteriosclerosis Obliterans
- Arthritis
- Arthritis, Rheumatoid
- Ascites
- Asthma
- Atherosclerosis
- Atrial Fibrillation
- Atrophy
- Attention Deficit and Disruptive Behavior Disorders
- Attention Deficit Disorder with Hyperactivity
- Autism Spectrum Disorder
- Autistic Disorder
- Behavioral Symptoms
- Biliary Tract Neoplasms
- Bipolar Disorder
- Body Weight
- Body Weight Changes
- Borderline Personality Disorder
- Brain Diseases
- Brain Ischemia
- Breast Neoplasms
- Cancer Pain
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Transitional Cell
- Cardiovascular Diseases
- Central Nervous System Diseases
- Cerebral Hemorrhage
- Cerebral Infarction
- Cerebral Small Vessel Diseases
- Child Development Disorders, Pervasive
- Cholangiocarcinoma
- Colitis
- Colitis, Ulcerative
- Colorectal Neoplasms
- Conduct Disorder
- Congenital Abnormalities
- Constriction, Pathologic
- Coronary Artery Disease
- Coronary Disease
- Crohn Disease
- Dementia
- Dementia, Vascular
- Depression
- Depressive Disorder
- Dermatitis
- Dermatitis, Atopic
- Diabetes Insipidus
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Digestive System Neoplasms
- Disease
- Dry Eye Syndromes
- Dyspepsia
- Eczema
- Edema
- Edema, Cardiac
- Emergencies
- Emphysema
- Endometrial Neoplasms
- Enteritis
- Enuresis
- Epilepsy
- Esophageal Neoplasms
- Esophagitis
- Esophagitis, Peptic
- Extensively Drug-Resistant Tuberculosis
- Fibrosis
- Gastritis
- Gastritis, Atrophic
- Gastroesophageal Reflux
- Gastrointestinal Neoplasms
- Gastroparesis
- Geographic Atrophy
- Glaucoma
- Glaucoma, Open-Angle
- Head and Neck Neoplasms
- Heart Diseases
- Heart Failure
- Hemorrhage
- Hepatic Encephalopathy
- HIV Infections
- Hypercholesterolemia
- Hyperkinesis
- Hyperlipidemias
- Hyperlipoproteinemias
Marketed drugs (14)
Subsidiaries (9 direct, 11 total across the full acquisition tree)
Recent trials (50)
- NCT04507503Lead sponsorN/A—
- NCT07225712OfficialPhase 3Dec 31, 2025
- NCT07225712Lead sponsorPhase 3Dec 31, 2025
- NCT07229339CollaboratorPhase 2Dec 1, 2025
- NCT07128199Lead sponsorPhase 3Nov 30, 2025
- NCT07173478OfficialPhase 3Oct 31, 2025
- NCT07173478Lead sponsorPhase 3Oct 31, 2025
- NCT07184645OfficialPhase 3Sep 30, 2025
- NCT07184645Lead sponsorPhase 3Sep 30, 2025
- NCT06971731Lead sponsorPhase 3Aug 31, 2025
- NCT07086313Lead sponsorPhase 2/Phase 3Aug 31, 2025
- NCT07086313OfficialPhase 2/Phase 3Aug 31, 2025
- NCT07087327OfficialPhase 3Aug 31, 2025
- NCT07087327Lead sponsorPhase 3Aug 31, 2025
- NCT06926829OfficialPhase 3Jun 25, 2025
Details
- Founded
- Tokyo, JP Jan 1, 1964
- First NDA
- Sep 17, 1996
- Last known activity
- Dec 31, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval